GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients.
WALTHAM, Mass. & MONZA, Italy--(BUSINESS WIRE)--
Thermo Fisher Scientific, the world leader in serving science, has received Good Manufacturing Practice (GMP) approval from the Italian Medicines Agency (AIFA) allowing the company to manufacture RNA-based products at its Monza, Italy site. The approval and associated certification support increased accessibility to novel therapies for patients with difficult to treat conditions, marking a significant achievement within the Thermo Fisher Scientific network and for Italy as a whole.
“RNA technology is being explored for a variety of modalities, including rare diseases and cancer which have limited treatment options,” said Dan Herring, General Manager, Advanced Therapies, Pharma Services at Thermo Fisher Scientific. “Obtaining AIFA GMP approval enables us to help our customers accelerate the development of new and life-saving therapeutics and vaccines for patients – and ultimately deliver on the promise of RNA-based technology.”
The Monza site specializes in drug product manufacturing in prefilled syringes, cartridges and vials. The approval of its GMP facility for RNA synthesis and lipid nanoparticle (LNP) formulation, plus its co-location with sterile fill and finish, supports an enhanced end-to-end solution for customers engaged in the development of RNA-based therapies and vaccines.
With more than 30 years of experience manufacturing sterile injectables, biologics, and advanced therapies, Thermo Fisher has the capabilities and expertise required to help customers accelerate development and increase access to therapies for patients globally.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20240118895171/en/
Media Contact Information:
Abbie Martin
Phone: (774) 847-4508
Email: abbie.martin@thermofisher.com
Source: Thermo Fisher